Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Undergraduate Student Research Awards (USRA)

University of Toronto

$6,000.00

Characterization of immune responses to sarcoma in vivo

EF 2026-27

Résumé
Soft tissue sarcomas (STS) such as undifferentiated pleomorphic sarcoma (UPS) are mesenchymal cancers for which there have been few advances in treatment over many decades. Approximately 50% of patients with UPS subsequently develop lung metastases and die despite aggressive chemotherapy. Therefore, new treatment approaches for patients with UPS are urgently needed. Immunotherapy has revolutionized cancer treatment for many types of cancer but is not yet approved in Canada for STS. We recently published a landmark randomized phase II clinical trial, SU2C-SARC032, that demonstrated that addition of anti-PD-1 immunotherapy to preoperative radiotherapy and surgery improved disease-free survival by 15% in UPS patients. Remarkably, our correlative studies from SU2C-SARC032 reveal that amongst the responders was a group of patients with immune cold sarcomas that responded to radiotherapy and anti-PD-1 with an influx of CD4 effector memory T cells. The goal of this project is to dissect mechanisms by which CD4 T cells contribute to antitumour response after radiotherapy and immunotherapy. We will use our novel genetically engineered mouse model of UPS with a defined neoantigen recognized by CD4 T cells to study the impact of radiotherapy and anti-PD-1 immunotherapy on the phenotype and function of tumour-specific CD4 T cells. Ultimately, we anticipate that these studies will provide the foundation to optimize radiotherapy and immunotherapy in future clinical trials to further improve outcomes in UPS and other "immune cold" cancers.
Programme
Undergraduate Student Research Awards (USRA)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
571660
Name
Obiji-Nnorom Ucheoma
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of immune responses to sarcoma in vivo
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Toronto
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Mesenchymal Cancers; Soft Tissue Sarcomas; Undifferentiated Pleomorphic Sarcoma
Abstract
Soft tissue sarcomas (STS) such as undifferentiated pleomorphic sarcoma (UPS) are mesenchymal cancers for which there have been few advances in treatment over many decades. Approximately 50% of patients with UPS subsequently develop lung metastases and die despite aggressive chemotherapy. Therefore, new treatment approaches for patients with UPS are urgently needed. Immunotherapy has revolutionized cancer treatment for many types of cancer but is not yet approved in Canada for STS. We recently published a landmark randomized phase II clinical trial, SU2C-SARC032, that demonstrated that addition of anti-PD-1 immunotherapy to preoperative radiotherapy and surgery improved disease-free survival by 15% in UPS patients. Remarkably, our correlative studies from SU2C-SARC032 reveal that amongst the responders was a group of patients with immune cold sarcomas that responded to radiotherapy and anti-PD-1 with an influx of CD4 effector memory T cells. The goal of this project is to dissect mechanisms by which CD4 T cells contribute to antitumour response after radiotherapy and immunotherapy. We will use our novel genetically engineered mouse model of UPS with a defined neoantigen recognized by CD4 T cells to study the impact of radiotherapy and anti-PD-1 immunotherapy on the phenotype and function of tumour-specific CD4 T cells. Ultimately, we anticipate that these studies will provide the foundation to optimize radiotherapy and immunotherapy in future clinical trials to further improve outcomes in UPS and other "immune cold" cancers.
Competitiondate
202605
Approvedterm2
0 yr 4 mths
Pinamesdelim
Obiji-Nnorom, Ucheoma
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $6,000~ $0~